Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

About this update from Eisai Co., Ltd.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/49c9e2c15a611e5a6b4b87fb40fa8c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xf.JqRVEDPx3YzvyMf8F6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/49c9e2c15a611e5a6b4b87fb40fa8c47","width":480,"height":270}},"lazy":false},{"type":"text","content":"Strategic collaboration expands taletrectinib global reach with a leading oncology partner","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"Eisai will receive exclusive development, registration and commercialization rights for taletrectinib for the treatment of ROS1-positive non-small cell lung cancer in Europe, Middle East, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India","length":296,"tagName":"p","attribs":{}},{"type":"text","content":"Nuvation Bio will receive double-digit tiered royalties up to the high-teens as a percentage of taletrectinib sales in the licensed territories, in addition to up to €195 million (approx. USD $230 million) in upfront and milestone payments","length":239,"tagName":"p","attribs":{}},{"type":"text","content":"Taletrectinib is already approved in the U.S., China and Japan for advanced ROS1-positive non-small cell lung cancer","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK & TOKYO, January 12, 2026--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., "Nuvation Bio"), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, today announced an exclusive license and collaboration agreement that significantly expands the long-term global footprint of taletrectinib (marketed as IBTROZI® in the U.S. and Japan). Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in ...

More updates from Eisai Co., Ltd.